Literature DB >> 26821335

Vascular Reactivity Profile of Novel KCa 3.1-Selective Positive-Gating Modulators in the Coronary Vascular Bed.

Aida Oliván-Viguera1, Marta Sofía Valero2, Estéfano Pinilla3, Sara Amor4, Ángel Luis García-Villalón4, Nichole Coleman5, Celia Laría2, Víctor Calvín-Tienza2, Ángel-Luis García-Otín2, José M Fernández-Fernández6, M Divina Murillo7, José A Gálvez8, María D Díaz-de-Villegas8, Ramón Badorrey8, Ulf Simonsen3, Luis Rivera9, Heike Wulff5, Ralf Köhler1,10.   

Abstract

Opening of intermediate-conductance calcium-activated potassium channels (KC a 3.1) produces membrane hyperpolarization in the vascular endothelium. Here, we studied the ability of two new KC a 3.1-selective positive-gating modulators, SKA-111 and SKA-121, to (1) evoke porcine endothelial cell KC a 3.1 membrane hyperpolarization, (2) induce endothelium-dependent and, particularly, endothelium-derived hyperpolarization (EDH)-type relaxation in porcine coronary arteries (PCA) and (3) influence coronary artery tone in isolated rat hearts. In whole-cell patch-clamp experiments on endothelial cells of PCA (PCAEC), KC a currents evoked by bradykinin (BK) were potentiated ≈7-fold by either SKA-111 or SKA-121 (both at 1 μM) and were blocked by a KC a 3.1 blocker, TRAM-34. In membrane potential measurements, SKA-111 and SKA-121 augmented bradykinin-induced hyperpolarization. Isometric tension measurements in large- and small-calibre PCA showed that SKA-111 and SKA-121 potentiated endothelium-dependent relaxation with intact NO synthesis and EDH-type relaxation to BK by ≈2-fold. Potentiation of the BK response was prevented by KC a 3.1 inhibition. In Langendorff-perfused rat hearts, SKA-111 potentiated coronary vasodilation elicited by BK. In conclusion, our data show that positive-gating modulation of KC a 3.1 channels improves BK-induced membrane hyperpolarization and endothelium-dependent relaxation in small and large PCA as well as in the coronary circulation of rats. Positive-gating modulators of KC a 3.1 could be therapeutically useful to improve coronary blood flow and counteract impaired coronary endothelial dysfunction in cardiovascular disease.
© 2016 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26821335      PMCID: PMC5720859          DOI: 10.1111/bcpt.12560

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  41 in total

1.  Use of intermediate/small conductance calcium-activated potassium-channel activator for endothelial protection.

Authors:  Qin Yang; Jun-Hao Huang; Yu-Bun Man; Xiao-Qiang Yao; Guo-Wei He
Journal:  J Thorac Cardiovasc Surg       Date:  2010-05-23       Impact factor: 5.209

2.  Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1.

Authors:  H Wulff; G A Gutman; M D Cahalan; K G Chandy
Journal:  J Biol Chem       Date:  2001-06-25       Impact factor: 5.157

3.  A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.

Authors:  Aida Oliván-Viguera; Marta Sofía Valero; Nicole Coleman; Brandon M Brown; Celia Laría; María Divina Murillo; José A Gálvez; María D Díaz-de-Villegas; Heike Wulff; Ramón Badorrey; Ralf Köhler
Journal:  Mol Pharmacol       Date:  2014-12-02       Impact factor: 4.436

Review 4.  Inducible endothelium-derived hyperpolarizing factor: role of the 15-lipoxygenase-EDHF pathway.

Authors:  William B Campbell; Kathryn M Gauthier
Journal:  J Cardiovasc Pharmacol       Date:  2013-03       Impact factor: 3.105

5.  Small- and intermediate-conductance calcium-activated K+ channels provide different facets of endothelium-dependent hyperpolarization in rat mesenteric artery.

Authors:  G J Crane; N Gallagher; K A Dora; C J Garland
Journal:  J Physiol       Date:  2003-10-10       Impact factor: 5.182

Review 6.  Patents related to therapeutic activation of K(ATP) and K(2P) potassium channels for neuroprotection: ischemic/hypoxic/anoxic injury and general anesthetics.

Authors:  Susan I V Judge; Paul J Smith
Journal:  Expert Opin Ther Pat       Date:  2009-04       Impact factor: 6.674

7.  Protein kinase A signalling is involved in the relaxant responses to the selective β-oestrogen receptor agonist diarylpropionitrile in rat aortic smooth muscle in vitro.

Authors:  Marta S Valero; Desiree Pereboom; Silvia Barcelo-Batllory; Laia Brines; Ricardo P Garay; José O Alda
Journal:  J Pharm Pharmacol       Date:  2011-02       Impact factor: 3.765

8.  Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant.

Authors:  H Wulff; M J Miller; W Hansel; S Grissmer; M D Cahalan; K G Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

9.  Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3.

Authors:  Aida Oliván-Viguera; Marta Sofía Valero; María Divina Murillo; Heike Wulff; Angel-Luis García-Otín; José-Miguel Arbonés-Mainar; Ralf Köhler
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

10.  Upregulation of SK3 and IK1 channels contributes to the enhanced endothelial calcium signaling and the preserved coronary relaxation in obese Zucker rats.

Authors:  Belén Climent; Laura Moreno; Pilar Martínez; Cristina Contreras; Ana Sánchez; Francisco Pérez-Vizcaíno; Albino García-Sacristán; Luis Rivera; Dolores Prieto
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

View more
  1 in total

Review 1.  Ischemic Heart Disease and Heart Failure: Role of Coronary Ion Channels.

Authors:  Paolo Severino; Andrea D'Amato; Mariateresa Pucci; Fabio Infusino; Lucia Ilaria Birtolo; Marco Valerio Mariani; Carlo Lavalle; Viviana Maestrini; Massimo Mancone; Francesco Fedele
Journal:  Int J Mol Sci       Date:  2020-04-30       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.